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INTRODUCTION
Hepatitis E is caused by infection with hepatitis E virus 
(HEV), which is a non-enveloped single-stranded RNA 
virus. Just like hepatitis A virus (HAV), HEV is usually 
transmitted from person-to-person via the fecal-oral route. 
Epidemic of  hepatitis E has been found in Central and 
South-East Asia, North and West Africa, and Mexico, 
where fecal contamination of  drinking water is common. 
However, recent reports showed that HEV occurs in 
individuals without traveling in HEV epidemic areas in 
developed countries like the United States of  America and 
Japan[1-5]. The application of  recently developed serologic 
tests has revealed anti-HEV in almost all countries, 
including developed countries, in which the disease 
virtually does not occur[6-8]. Possible reservoirs of  HEV 
in the developed countries may be found in animals like 
monkeys, pigs, cows, rodents, sheep or goats, suggesting 
that HEV may be zoonotic[9-12]. Xia et al[13] reported that 
acute hepatitis E occurs in rhesus monkeys, indicating that 
transfusion transmits hepatitis E. Hepatitis-E is a self-
limited disease. But a current research indicates that there 
are cis-reactive elements in HEV ORF3 [14]. Surjit M et al[15] 
found that enhanced alpha microglobulin secretion from 
Hepatitis E virus ORF3-expressing human hepatoma cells 
is mediated by the tumor susceptible gene 101. HEV is 
highly epidemic in China and it is very important for us to 
find a reliable assay for diagnosing its acute, sub-clinical 
and chronic infection.
Immunoglobulin M (IgM) against HEV (anti-HEV 
IgM) is used as a reliable and sensitive marker for recent 
HEV infection[16-19]. However, the specificity of  solid-
phase assay for anti-HEV IgM has been questioned 
in patients with IgM-rheumatoid factors in serum. It 
was reported that anti-HEV IgA can be utilized as an 
additional complementary antibody for detecting recent 
HEV infection[20-23]. But the clinical and epidemiological 
implications of  anti-HEV IgA in finding HEV infection 
remain to be clarified.
In this study, we used the solid-phase assay to detect 
HEV-specific IgA. The kinetics of  anti-HEV IgM, anti-
HEV IgA and anti-HEV IgG responses in serum from 
patients with hepatitis E demonstrated that anti-HEV IgA 
assay could identify HEV infection.
MATERIALS AND METHODS
Serum samples
This study enrolled 100 patients (77 males and 23 females, 
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Abstract
AIM: To study the significance of serum anti-hepatitis E 
virus (HEV) IgA in patients with hepatitis E.
METHODS: A new method was established to assay 
anti-HEV IgA, which could be detected in the middle 
phase of the infection. We compared anti-HEV IgA assay 
with anti-HEV IgM and anti-HEV IgG assay in sera from 
60 patients with positive HEV-RNA. 
RESULTS: The 60 patients with positive HEV-RNA had 
both anti-HEV IgA and anti-HEV IgM and 410 patients 
with negative HEV-RNA were used as control. Periodic 
serum samples obtained from 60 patients with hepatitis 
E were tested for HEV RNA, anti-HEV IgM, anti-HEV 
IgA and anti-HEV IgG. Their HEV-RNA was detectable 
in the serum until 20 ± 11 d. We used anti-HEV IgM 
and anti-HEV IgA assay to detect HEV infection and 
positive results were found in 90 ± 15 d and 120 ± 23  d 
respectively, the positive rate of anti-HEV IgA was higher 
than that of anti-HEV IgM and HEV-RNA (P  <0.05).
CONCLUSION: The duration of anti-HEV IgA in serum 
is longer than that of anti-HEV IgM, and anti-HEV IgA 
assay is a good method to detect HEV infection.
© 2006 The WJG Press. All rights reserved.
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mean age 52 ± 11 years ) with acute hepatitis E admitted 
to the Department of  Infectious Diseases of  Tongji Hos-
pital in Wuhan, China, during the period of  August 2003 - 
August 2004. Sera were collected from 60 HEV-RNA pos-
itive patients on d 15, 30, 60, 90 and 120 after the onset of  
symptoms. In addition, 410 serum samples obtained from 
HEV-RNA negative patients (304 males and 106 females, 
mean age 42 ± 9 years) were used as controls, including 
100 samples from voluntary blood donors with normal 
alanine aminotransferase (ALT) level, 218 samples from 
patients with hepatitis A, B or C, 52 samples from patients 
with autoimmune hepatitis, 40 samples from patients with 
rheumatoid arthritis. Liver function tests included total se-
rum bilirubin (T-Bil) and direct bilirubin(D-Bil, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase, total protein, g-glutamyltranspepti-
dase, prothrombin time, and total cholesterol levels. The 
serum samples were stored at -70℃ until HEV RNA test.
The presence of  anti-HAV IgM, hepatitis B surface 
antigen (HbsAg), hepatitis B e antigen (HbeAg), antibodies 
to HBV core (anti-Hbc), and anti-HCV was determined 
with commercially available kits.
RNA extraction and RT-PCR
Total RNA was extracted with guanidinium isothio-
cyanate. RT-PCR was carried out in a 50 mL reaction 
volume containing 10 mL purified RNA, 25 pmol each 
primer, 1 mL AMV reverse transcriptase and 0.5 mL Taq 
polymerase. Thirty-five cycles of  PCR amplification were 
performed at 94℃ for 1 min, at 52℃ for 45 s, at 72℃ for 1 
min, and a final extension at 72℃ for 7 min. Second-round 
reactions were carried out in a volume of  50 mL containing 
10 mL first-round product, 25 pmol each primer and 0.5 
mL Taq polymerase. Thirty PCR omplification cycles were 
performed at 94℃ for 1 min, at 52℃ for 45 s, at 72℃ 
for 1 min, and a final extension at 72℃ for 7 min.
Consensus oligonucleotide primers for ORF2 were 
designed within regions of  conserved sequences in 
the full-length sequences from Asia, Mexico, USA and 
China strains. The ORF2 primers, at positions 5681nt-
6486nt, produced a product of  805 bp nucleotide: EP1 
(5´-GCTTCAAATTATGCCCAGTA-3’) and EP2 (5’
-TGTTGGTTGTCATAATCCTG-3’). Second round 
internal primers amplified 345 bp products for ORF2: EP3 
(5´-GTTATGCTTTGCATA(T)CATGG-3’) and EP4 (5’
-CCGACGAAATCAATTCTGTC- 3’).
Sequence analysis
Second-round PCR products were purified and ligated into 
pMD 18-T vectors. Twenty-five clones were sequenced 
automatically with an ABI model - 3730 DNA sequencer 
and the ABI sequencing ready reaction kit (Perkin - Elmer) 
according to the manufacturer’s instructions. Sequences 
used for phylogenetic analysis were obtained from Mexico 
(GenBank accession no. M74506 ), Burma (D10330), USA 
(AF060669), China (C1, AJ272108; C2, AF103940; C3, 
AF151963).
Phylogenetic analysis
Nucleotide sequences were aligned using Clustalx 1.81 
(http://downloads.scalableinformatics.com/downloads/
clustalx/). These alignments were analyzed with Mega 2.0 
(http://evolution.genetics.washington.edu/phylip/soft-
ware.html) to evaluate the evolutionary distances between 
sequences using 1000 bootstraps of  the data. Bootstrap 
values greater than 70% could provide significant evidence 
for phylogenetic analysis grouping.
ELISA for anti-HEV-IgM and anti-HEV-IgG
Anti-HEV-IgM and anti-HEV-IgG were detected by us-
ing commercially available kits (BeiJing Wantai Biological 
Pharmacy Enterprise Co., LTD.). Absorbance (A) value 
was measured at 450 nm. Anti-HEV-IgM cut off  = 0.26 
+ negative control mean A value, Anti-HEV-IgG cut off  
= 0.16 + negative control mean A value. Samples with A 
values > cut off  were considered positive, Samples with A 
values ≤ cut off  were considered negative.
ELISA for anti-HEV-IgA 
ELISA for detection of  IgG using purified recombinant 
ORF2/ORF3 protein (WanTai biological pharmacy en-
terprise co. LTD.) was performed with HRP-labeled coat 
monoclonal anti-human IgA (Wuhan Lingfei Science and 
Technology Limited Company) in stead of  HRP-labeled 
coat monoclonal anti-human IgG. In order to detect the ti-
ters of  goat anti-human IgA-HRP, ELISA was performed 
with 6 diluted concentrations: 1:500,1:1000,1:2000, 
1:4000,1:8000,1:16000. Results demonstrated that P/N 
(ratio of  sample A to negative A) of  1:4000-1:8000 of  
diluted antibodies was ≥ 2.0. In order to obtain the stably 
detectable results, the diluted concentration of  1:4000 was 
adopted as standard one and 410 sera with negative HEV-
IgM and HEV–IgG were detected for HEV-IgA.
Statistical analysis
Chi square test was used for statistical analysis.
RESULTS
Among the 100 acute phase sera with hepatitis E, 60 
(60%) were positive for HEV RNA by reverse transcrip-
tion- nested polymerase chain reaction (RT- nPCR) using 
the degenerated primers. Among which 25 partial ORF2 
sequences (5972-6317 nt) belonging to HEV genotype Ⅳ 
were analyzed. 
HEV RNA in serum samples from 100 donors nega-
tive for anti-HEV-IgM and anti-HEV-IgG was detected by 
anti-HEV-IgA assay. The absorbance (A) was set at 0.128, 
standard deviation (SD) at 0.053. When critical value was 
set at A + 2SD, the IgA assay results were all negative in 
410 HEV-IgM and -IgG negative sera. When the A  value 
of  positive HEV-IgA assay was set as the mean value of  
negative control plus 0.18, the specificity of  anti-HEV 
IgA was verified by absorption with the same recombinant 
ORF2 protein (50 mg/L at the final concentration for anti-
HEV IgA assay). Briefly, prior to assay, 10 serum samples 
were diluted at 1:100, 1:500, 1:1000, 1:5000 to make its A 
value < 1.5. The microwells were incubated at 37℃ for 
0.5 h, then at 4℃ overnight. When the ten serum samples 
were diluted at 1:500,the A value of  the tested samples 
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was reduced by ≥ 75% in the anti-HEV IgA assay with 
the recombinant ORF2 protein, the sample was considered 
positive for anti-HEV.
Among the serum samples obtained from 100 blood 
donors, only one sample was positive for anti-HEV IgM, 
and two samples were positive for anti-HEV IgA. The 
same samples were positive for anti-HEV IgG and HEV 
RNA. Using the cutoff  values, among remaining 310 se-
rum samples obtained from 62 patients with hepatitis A, 
100 patients with hepatitis B, 56 patients with hepatitis C, 
52 patients with autoimmune hepatitis, 40 patients with 
rheumatoid arthritis, were tested for anti-HEV IgA, anti-
HEV IgM and anti-HEV IgG (Table 1). Among the 410 
patients who were not infected with HEV, including the 
100 blood donors, anti-HEV IgM was positive in 7 serum 
samples, including 2 from patients with hepatitis, 4 from 
patients with autoimmune disorders. Anti-HEV IgA was 
detected in 6 serum samples including 4 from patients with 
hepatitis. The positivity for HEV antibodies could not be 
confirmed by the absorption test in any of  the 10 samples. 
Serum samples obtained from 100 patients with sporadic 
acute hepatitis E were tested for the presence of  IgM and 
IgA anti-HEV antibodies. All the 100 patients were posi-
tive for anti-HEV IgM and anti-HEV IgA. The presence 
of  anti-HEV IgM and anti-HEV IgA was confirmed by 
the absorption test in the serum samples from all 100 pa-
tients. HEV IgA assay was highly specific and false- posi-
tive results in HEV-IgG and IgM assay could also be found 
in the IgA assay (Table 1). 
Anti-HEV IgA, IgM and HEV-RNA were positive in 
patients with early HEV infection. HEV RNA remained 
detectable in the serum for one month, anti-HEV IgA for 
four months (> 50%, anti-HEV IgM for three months (> 
50%), ALT and T-Bil for four months (Table 2).
DISCUSSION
Although the incidence of  acute hepatitis especially acute 
hepatitis E has been gradually increased, the correct diag-
nosis of  HEV infection largely depends on the sensitivity 
and specificity of  HEV assay kits. The golden diagnosis 
standard for acute hepatitis E is based on detection of  the 
HEV genome in serum or feces by RT-PCR, but it can 
only be used for earlier diagnosis. A solid-phase (sandwich 
or indirect) ELISA for detecting anti-HEV IgM and IgG 
is simple and has been currently used in diagnosis of  HEV 
infection[24]. One of  its disadvantages is the reduced sen-
sitivity due to competition among virus-specific IgM, IgA 
and IgG for antigen-binding sites. Another potential dis-
advantage of  the solid-phase test for IgM antibody is that 
IgM-rheumatoid factor in sera from patients with rheuma-
toid arthritis may produce a false-positive result. Although 
the existence of  anti-HEV IgG in serum is very long, we 
cannot distinguish current acute infection from the last 
infection. It is important to find a new diagnosis assay. It 
has been reported that anti-HEV IgA can be utilized as an 
additional confirmatory antibody for recent HEV infec-
tion[25]. Although the presence of  a specific antibody of  
IgA can show recent infection in several viral or nonviral 
diseases, including hepatitis A and B as well as cholera[26], 
the clinical and epidemiological significance of  positivity 
for anti-HEV IgA remains to be fully verified.
In the present study, we used ELISA to detect IgA 
using HRP-labeled coat monoclonal anti-human IgA in 
stead of  HRP-labeled coat monoclonal anti-human IgG. 
The results showed both anti-HEV IgM and anti-HEV 
IgA were detectable in serum samples obtained from all 
60 patients tested who were subsequently diagnosed with 
HEV infection. The sensitivity was 100%. Among the 410 
serum samples from subjects not recently infected with 
HEV, 6 were falsely positive for anti-HEV IgM and 5 were 
falsely positive for anti-HEV IgA, indicating that the false-
positive rate is low both in anti-HEV IgM and in anti-
HEV IgA. Except for one occult HEV infection, none was 
positive for both anti-HEV IgM and anti-HEV IgA. The 
specificity of  anti-HEV IgA was verified in the absorbant 
and inhibitory assay. 
HEV RNA, anti-HEV IgA, anti-HEV IgM, ALT and 
TBiL were defected in serum samples from 60 infected 
patients during follow-up. From these 60 patients, the 
serum samples obtained on d 15, 30, 60, 90 and 120 after 
the disease onset. The period of  apparent manifestations 
was 40 d, liver disfunction usually lasted 5 mo, the peak of  
alanine aminotransferase and total bilirubin was 246 ± 53 
U/L and 506 ± 123 mmol/L respectly. The positive num-
ber of  HEV RNAs in serum was 60 (100%), 36 (60%), 3 
(5%) and 0 in wk 2, mo 1-3 respectly. The positive number 
of  anti-HEV IgA was 60 (100%), 60 (100%), 58 (97%), 56 
(93%), 38 (63%), 18 (30%) in the second week, the first 
Table 1  Prevalence of anti-HEV IgM and anti-HEV IgA in 
different groups of subjects
Table  2 Serum anti-HEV IgA, anti-HEV IgM, HEV RNA, ALT 
and TBil
                                               Anti-HEV  Anti-HE  Anti-HEV  HEV
Group               n         Age           IgA,         IgM,     IgG,       RNA, 
                            (mean ± SD)   n  (%)       n  (%)    n  (%)     n  (%)
Hepatitis A   62 33.1 ± 11.2     2 (3.2)     1 (1.6)   1 (1.6)   0
Hepatitis B 100 36.3 ± 12.2     1 (1)     0 10 (10)   0
Hepatitis C   56 45.6 ± 15.3     1 (1.8)     1 (1.8)   1 (1.8)   0
Autoimmune
 hepatitis
  52 40.5 ± 10.1     0     2 (3.8)   3 (5.8)   0
Rheumatoid
 arthritis
  40 56.4 ± 9.4     0     2 (5)   1 (2.5)   0
Blood donors 100 36.8 ± 18.5     2 (2)     1 (1)   8 (8)   1 (1)
Hepatitis E 100 52.6 ± 14.8 100 (100) 100 (100) 98 (98) 60 (60)
            HEV     Anti-HEV  Anti-HEV  Anti-HEV     ALT        TBil (mean
T/mo    RNA     -IgA          -IgM        -IgG       (mean ± SD)  ± SD)
           n (%)      n  (%)      n  (%)     n  (%)          nkat/L         mmol/L
-0.5 60 (100) 60 (100) 60 (100) 59 (98) 1117 ± 200   86 ± 17
-1 36 (60) 60 (100) 60 (100) 60 (100) 4101 ± 884 506 ± 123
-2   3 (5) 58 (97)a 46 (77) 60 (100) 1850 ± 750 198 ± 68
-3   0 56 (93)b 34 (57) 60 (100)   800 ± 250   84 ± 31
-4   0 38 (3)b 12 (20) 60 (100)   567 ± 183   46 ± 14
-5   0 18 (0)b   2 (3) 60 (100)   467 ± 150   23 ± 8
aP < 0.05, bP< 0.01 compared with anti-HEV IgM positive results.
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1-5 mo after the disease onset, respectively. The positive 
number of  anti-HEV IgM was 60 (100%), 60 (100%), 46 
(77%), 34 (57%), 12 (20%), 2 (3%) in the second week, the 
first 1-3 mo, respectively. The positive rate of  anti-HEV 
IgM and anti-HEV IgA was not significantly different in 
the first month after the disease onset. From the second 
month, the positive rate of  anti-HEV IgM decreased 
sharply. The positive rate of  anti-HEV IgA maintained at 
a high level. There were significant changes in them (P < 
0.05). Since the duration of  sero-positivity for HEV RNA, 
anti-HEV IgM and anti-HEV IgA lasted 1, 3 and 4 mo 
respectively,hepatic dysfunction lasted 4 mo, the diagnosis 
of  HEV infection could be made by assay of  anti-HEV 
IgM and anti-HEV IgA. Anti-HEV IgA and anti-HEV 
IgG can be used as a diagnostic indicator of  HEV without 
anti-HEV IgM. 
We have previously reported that indirect ELISA can 
detect anti-HEV IgG and anti-HEV IgA. The perfor-
mance of  IgA test has been extensively evaluated[27,28]. The 
assay specificity, sensitivity, and consistency are carefully 
documented. Based on the results obtained in the study, 
we conclude that anti-HEV IgA assay is as specific as the 
anti-HEV IgM assay in diagnosis of  hepatitis E. IgM and 
IgA anti-HEV tests can be used together to characterize 
serum specimens with non-acute hepatitis E. Detecting 
both IgM anti-HEV and IgA anti-HEV at the same time 
help to minimize the false positive rate, thus improving di-
agnosis of  HEV infection.
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